Search for a trial

BIOFLOW-V: BIOTRONIK * A Prospective Randomized Multicenter Study to Assess the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions * V

To assess the safety and efficacy of the Orsiro Sirolimus Eluting Coronary Stent System in the treatment of subjects with up to three native de novo or restenotic (standard PTCA only) coronary artery lesions compared to the Xience coronary stent…

Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an
All COmeRs PopulaTion (BIO-RESORT): Randomized Multicenter Trial in an All Comers Population Treated Within thE NeThErlands 3 (TWENTE 3)

The aim of the study is to compare the outcome of two DES with biodegradable polymer coatings separately (Orsiro and Synergy) versus an established third-generation durable polymer DES with proven efficacy and safety (Resolute Integrity) in an all…

BIOTRONIK- *A Prospective, Randomized, Multicenter Study to Assess the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Stent in the Treatment Of Subjects With up to two de novo Coronary Artery Lesions* - IV

To evaluate the safety and effectiveness of Orsiro for the treatment of subjects with up to 2 de novo atherosclerotic coronary artery lesions.

A phase IV, randomized, open label, cross-over, intervention trial to investigate the effect of the switch of protease inhibitors to raltegravir on endothelial function, chronic inflammation, immune activation and HIV replication below 50 copies/ml

1. To assess the effect of the switch from protease inhibitors to raltegravir on endothelial function. 2. To assess the effect of the intervention mentioned above on markers of endothelial function; immune activation; chronic inflammation; and, on…

Randomized trial of Legflow® Paclitaxel eluting balloon (LPEB) with stentplacement vs. standard PTA with stentplacement for the treatment of intermediate (>5 cm and < 15 cm) and long (>15 cm) lesions of the superficial femoral artery (SFA). The RAPID trial.

The primary objective is to assess the difference in absence of binary restenosis rate of endovascular treatment of intermediate and long lesions of the superficial femoral artery with the Legflow® PEB and nitinol stent, when compared to uncoated…

Does the use of paclitaxel coated balloons inhibit restenosis in hemodialysis fistula? Results compared to conventional PTA balloons in a randomised trial.

Our objective is to evaluate the patency of paclitaxel coated balloons in hemodialysis patients presenting at the radiology department more than once a year with repetitive severe stenoses of their fistula, and compare the results with primary…

EFFECTS OF ANGIOTENSIN-RECEPTOR BLOCKADE WITH OLMESARTAN ON CAROTID ATHEROSCLEROSIS IN PATIENTS WITH HYPERTENSION: THE CONFIRMATORY OLMESARTAN PLAQUE REGRESSION STUDY (CONFIRM)

The primary efficacy variable is the change in PV from baseline as assessed by 3 D ultrasonography after 78 weeks of double-blind treatment with OM 20-40 mg daily compared to ATE 50-100 mg daily.Secondary efficacy variables:Change from baseline PV…

Prospective, Randomized, Controlled, Multicentre, Open Study Releas of Paclitaxel during PTA versus PTA alone for the treatment of de-novo occluded, stenotic or reoccluded, restenotic superficial femoral (SFA) or popliteal arteries.

The study investigates the inhibition of restenosis by the Paclitaxel-eluting PTA balloon Freeway versus stenting-PTA or PTA alone in the treatment of de-novo occluded, stenotic or reoccluded, restenotic superficial femoral (SFA) or popliteal…

Euroaction plus intensive smoking intervention (varenicline)

A practical demonstration project in 5 European countries to show that intensive smoking intervention during a preventive cardiovascular risk management programme for patients with cardiovascular (CVD) or other atherosclerotic disease, asymptomatic…

Effects of low-dose aspirin taken at bedtime vs. on awakening on circadian rhythm of platelet function in healthy subjects

To study the effect of 80 mg aspirin intake at bedtime compared with 80 mg aspirin intake on awakening on circadian rhythm of platelet function in healthy subjects.

A randomised, double blind, parallel-group study of the oxidative stress lowering effect of simvastatin and atorvastatin.

To compare the rapidity of onset and the extent of oxidative stress lowering of atorvastatin with that of an (in terms of LDL lowering) equipotent dosage of simvastatin.

Cryoplasty of the femoropopliteal arteries in patients with intermittent claudication compared with conventional angioplasty: a randomized study

Our aim is to evaluate the patency of cryoplasty in patients with intermittent claudication or critical ischemia, where exercise training is ineffective. Furthermore, we will evaluate whether cryoplasty will significantly improve the quality of life…

The effects of aspirin on the platelet function of healty volunteers and of patients with occlusive arterial vascular disease.

Objective of the study is to investigate the effects of aspirin on the platelet function of healthy volunteers and of patients with ischemic stroke. In another part of the study, we will investigate whether or not the effects of aspirin on the…

Aspirin sensitivity in diabetes mellitus;
the role of glycaemic control and dosing

The main objective of this study is to determine the role of glycaemic control in diabetes mellitus in the occurrence of acetylsalicylic acid resistance, the secondary objective is to determine the effect of increased dosing on acetylsalicylic acid…

Does Applying More Oxygen Cure Lower Extremity Sores?

To assess the relative effectiveness of HBOT as an adjunct to standard wound care in terms of preventing amputations and improving wound healing in ischemic diabetic ulcers, and its cost-effectiveness. Secondary objectives are to assess the patients…

A phase 4, monocenter, randomized, double-blind, comparator-controlled, parallel-group, mechanistic intervention trial to assess the effect of 12-week treatment with the sodium-glucose linked transporters (SGLT)-2 inhibitor dapagliflozin versus the sulfonylurea (SU) derivative gliclazide on renal physiology and biomarkers in metformin-treated patients with type 2 diabetes mellitus (T2DM)

To gain more knowledge about the effects of SGLT2 inhibition on renal hemodynamics and the underlying mechanisms.

A phase 4, monocenter, randomized, double-blind, comparator-controlled, 3-armed parallel mechanistic intervention trial to assess the effect of 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, followed by 8-week empagliflozin and linagliptin (DPP-4 inhibitor) combination therapy versus 8-week linagliptin monotherapy, followed by 8-week linagliptin and empagliflozin combination therapy versus 8-week gliclazide (Sulfonylurea derivate), followed by 8-week gliclazide intensification therapy on r

To examine the effects of mono- and combination therapy with linagliptin and empagliflozine on renal hemodynamics

BIoresorbable polymer-coated ORSIRO versus durable polymer-coated RESOLUTE ONYX stents [BIONYX]: A randomized Trial With stENT Evaluation in all-comers IV [TWENTE IV]

The aim of the study is to compare the outcome of the bioresorbable polymer coated stent (ORSIRO) and a new generation permanent polymer coated stent (RESOLUTE ONYX) in an allcomers patient population and non-inferiority setting.

Tailoring P2Y12 Inhibiting Therapy in Patients requiring Oral Anticoagulation after undergoing Percutaneous Coronary Intervention: The Switching Anti-Platelet and Anti-Coagulant Therapy - 2 Study

The aim of this study is to assess the pharmacodynamic effects of different P2Y12 inhibiting therapy (clopdiogrel vs ticagrelor) in patients at high risk for HPR identified according to the ABCD-GENE score in PCI treated patients also requiring OAC…

Genotype-guided strategy for antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease.

This study has been transitioned to CTIS with ID 2024-518122-33-00 check the CTIS register for the current data. The primary aim of the GENPAD study is to evaluate the ability of genotype-guided antithrombotic treatment to reduce adverse clinical…